NIH | National Cancer Institute | NCI Wiki  

Date

Attendees

Committee MemberPresentAbsent
Kuffel, Gina (NIH/NCI) [C]
X
Amy LeblancX

Otridge, John (NIH/NCI) [C]

X
Kim, Erika (NIH/NCI) [E]
X

Sommers, Connie (NIH/NCI) [E]


X
Debbie Knapp
X
Toby HechtX
Ralph ParchmentX

Goals

  • Discuss updates to ICDC and define emerging strategies and priorities

SharePoint Site

https://nih.sharepoint.com/sites/NCI-CBIIT-FNL-ICDC-ICDCLeadershipGroups

Outstanding Action Items

  • Debbie to work with Ralph to write invitation for Jaime Modiano
  • Revisit new steering committee members in September (loop Connie into this discussion) 

Agenda

ItemWhoTalking Points
Continue discussion of potential submission of FidoCure  Animal Health data

Debbie Knapp

  • We asked FidoCure if they had data on glioma, osterosarcoma, bladder cancer, mucosal and acral melanoma, and mast cell tumor.

    • Gerry Post replied “We do have data on osteosarcoma, mast cell tumors and some acral melanomas. As for gliomas and urothelial carcinomas, biopsies are much less common so we have less data.” Although he does not specify, I would think they would have lots of data on mucosal oral melanoma too.
    • If we want to pursue this further, I think Gerry would like a more specific request that he will then take to his board.
Potential collaboration with the Data for the Common Good (DCG) team and possibly a new working group

Kim, Erika (NIH/NCI) [E] 

  • DCG are interested in helping end users identify related cases between canine and pediatric oncology
    • Building consensus data standards between human and canine data elements
    • Mapping existing data elements in the ICDC to NCIT codes to facilitate the findability of canine data related to human data through platforms such as the Cancer Data Aggregator.   
DGAB Updates

Kuffel, Gina (NIH/NCI) [C] 

Recently Released

ICDC Studies in Active Submission

  • COTC021
    • Approved by SAC on 6/30/23
    • "Evaluation of Orally Administered mTOR inhibitor Rapamycin in Dogs in the Adjuvant Setting with Osteosarcoma"
    • Dr. Amy LeBlanc
    • Status: Working with data submitters to provide AWS creds
BPSC Updates

Kuffel, Gina (NIH/NCI) [C] 

  • Should we repurpose the Best Practices Subcommittee to form the new Data Standardization Team?
  • Should we create an outline of the goals and some next steps for aligning canine data properties and values to a controlled vocabulary?
  • Which controlled vocabularies should we consider (NCIT, SnoMed, etc.)
Upcoming Steering Committee Meeting

Ralph Parchment

  • December meeting: 12/15/23
  • Ralph will send out the minutes for approval

Minutes (Not Verbatim)

TH - Golden Retriever Lifetime study has contacted us with biospecimen data, they would like a discussion. Could we have a page within the application to redirect users to biospecimen data? We could let them know about the potential for displaying URLs for their biospecimen data. We could organize this data by type (ie. plasma, mast cell, circulating tumor cells, etc.), we could provide contact information at the consortium level).

JO - This can serve as a maturation of what the ICDC can do.

RP - It is possible that some of the golden retrievers are still being monitored. 

AL - Goldens are susceptible to all sorts of issues and diseases, it would be important to understand if they capture cancer specimens and diagnostic information.

EK - Sam is funded by the CCDI and is building data dictionaries for CCDI, confirming with the program that a collaboration would be supported.

JO - We are already working with Sam to implement platforms for CCDI.

TH - Gliomas can be studied in canine and pediatric data

AL - Osteosarcoma is another link

TH - In PRECINCT there was a trial in glioma that showed the significance between canine and pediatric data

JO - Another important resource to display within the ICDC could be relevant links to clinical trials from CCDI.

TH - We need to invite a rep from Pediatric Oncology to join the Steering Committee (could be a radiologist).

TH - We need to first figure out the plan of action for mapping canine/pediatric data and common data elements.

JO - Katherine Janeway from Dana Farber can be a potential 

AL - Ronnie Roberts from Nationwide Children's hospital

TO - Adam Resnick from CHOP could be a potential collaborator, he focuses on gliomas. 

AL - There is a new veterinary journal coming under the umbrella of Nature, I will be a co-editor, titled Nature Veterinary Oncology, I wanted to ask for a submission about the ICDC, perhaps a perspectives piece.


Previous ICDC Use Cases from Steering Committee

1. Genomic correlates across platforms (DNA, RNA, protein).

2. Correlating multi-omics data with clinical annotation and phenotypes, particularly outcomes.

3. Comparative analyses of canine and human. Examples include:

1. Search for conserved mutations between canine and human tumors

2. Disease diagnosis (e.g. cancer type) and classification mapping between canines and humans

5. Gene expression changes and mutational profiles associated with therapeutic response and outcome

6. How do sporadic tumors in non-human mammals compare to sporadic human tumors?

7. Correlations and model building from radiomic and pathomic features extracted from medical and histopathologic images with outcomes and genomics, as is currently being widely done with human images

8. Develop biomarkers of response and resistance in humans by analyzing the responses and genomic signatures in dogs.

Action items

  • Gina to speak with Debbie to arrange a meeting with Gerry to discuss data submission (Toby, Debbie, Phil)
  • Toby to invite Greg from CCDI to the next Executive Team Meeting in January
  • Toby to look across the NCI directory to find person that has a combination of canine and pediatric oncology background